How is zegalogue different from a standard glucagon kit?

What's the key difference between Zegalogue and a standard glucagon kit?

Zegalogue, also known as dasiglucagon, is a glucagon-like peptide-1 (GLP-1) receptor agonist, whereas standard glucagon kits contain human glucagon, a hormone that helps regulate blood sugar levels [1]. Glucagon in standard kits is a fast-acting injectable used to treat severe hypoglycemia (low blood sugar).

Why does Zegalogue stand out from standard glucagon kits?

Zegalogue is a recombinant GLP-1 receptor agonist, made using DNA technology, which is easier to manufacture and has a longer shelf life compared to human glucagon [2]. Additionally, Zegalogue has a longer duration of action, requiring only a single administration [3]. This makes it easier for patients and caregivers to use, especially in emergency situations.

How does Zegalogue's mechanism differ from standard glucagon?

While both drugs increase blood sugar levels, Zegalogue works by binding to the GLP-1 receptor, which stimulates insulin production and inhibits glucagon release [4]. Standard glucagon kits, on the other hand, directly stimulate glucagon release, which increases blood sugar levels by promoting glucose release from stored sources.

When does Zegalogue gain exclusivity, and when can biosimilars enter the market?

The patent for Zegalogue (dasiglucagon) is held by Zealand Pharma, but no information is available for the expiration date of the patent [5]. As a recombinant human GLP-1 receptor agonist, biosimilars that are structurally similar but not identical can potentially enter the market after the patent expires.

Sources:

[1] - https://www.drugpatentwatch.com/#/drug/1595 (Search for Dasiglucagon)
[2] - https://www.drugpatentwatch.com/drug-profiles/1595/ (Search for Dasiglucagon)
[3] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941410/
[4] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481115/
[5] - https://www.drugpatentwatch.com/#/drug/1595 (Search for Dasiglucagon)